NovaBridge Biosciences (NBP) has outlined a series of near-term catalysts across its oncology and ophthalmology programs, positioning the company for multiple data readouts and conference presentations in 2026 and 2027.
The company's pipeline includes Givastomig, VIS-101, Ragistomig, and Uliledlimab, each advancing in clinical development with anticipated milestones ahead.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com